PROF PROF
Company Profile ↓Company Overview
PROF (PROF) is a publicly traded company listed on with a market capitalization of $289.99M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 34.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $16.10M (+50.7% YoY); net profit $-42.57M.
- Trailing 12 Months Year-on-year growth — revenue +50.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.06% |
| 1 Year: | 50.73% |
Stock Price Performance
| 1 Year: | +40.42% |
| 6 Months: | +13.17% |
| 3 Months: | +9.90% |
| 1 Month: | +7.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.97 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22M | 1.95M | 2.54M | 2.62M | 2.21M | 5.29M | 5.98M | 5.34M |
| Cost of Revenue | - | - | - | 768.00K | 593.00K | 1.36M | 1.99M | 1.50M |
| Gross Profit | 866.00K | 1.42M | 1.79M | 1.85M | 1.62M | 3.93M | 3.99M | 3.83M |
| Operating Expenses | - | - | - | 13.02M | 15.42M | 12.84M | 11.36M | 11.85M |
| Operating Income | -7.88M | -7.84M | -9.00M | -11.17M | -13.81M | -8.91M | -7.37M | -8.02M |
| EBITDA | - | - | - | -11.00M | -13.66M | -8.77M | -7.26M | -7.92M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -10.68M | -15.63M | -7.86M | -8.15M | -7.03M |
| Tax Provision | - | - | - | 41.00K | 64.00K | 121.00K | 26.00K | 25.00K |
| Net Income | -6.58M | -6.92M | -9.37M | -10.72M | -15.70M | -7.98M | -8.18M | -7.05M |
| Diluted EPS | 0.27 | 0.28 | 0.38 | -0.36 | -0.52 | -0.26 | -0.27 | -0.19 |
| R&D Expense | 3.94M | 4.21M | 4.17M | 4.81M | 6.10M | 5.42M | - | 5.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 6.68M | 7.20M | 10.68M | 16.10M |
| Cost of Revenue | - | 3.66M | 2.89M | 3.64M | 4.71M |
| Gross Profit | - | 3.02M | 4.31M | 7.04M | 11.39M |
| Operating Expenses | - | 32.62M | 32.96M | 40.10M | 52.65M |
| Operating Income | - | -29.60M | -28.65M | -33.06M | -41.25M |
| EBITDA | - | -26.60M | -27.72M | -32.13M | -40.69M |
| Interest Expense | 67.00K | 174.00K | 770.00K | - | - |
| Pretax Income | - | -28.38M | -28.45M | -27.82M | -42.32M |
| Tax Provision | - | 287.00K | -128.00K | -2.00K | 252.00K |
| Net Income | - | -28.67M | -28.32M | -27.82M | -42.57M |
| Diluted EPS | - | -1.38 | -1.34 | -1.12 | -1.41 |
| R&D Expense | - | - | 14.42M | 16.96M | 20.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 64.42M | 43.96M | 70.23M | 77.47M |
| Current Assets | - | 62.02M | 41.90M | 69.06M | 76.09M |
| Cash & Equivalents | - | 46.52M | 26.21M | 54.91M | 59.72M |
| Inventory | - | 7.94M | 6.99M | 5.80M | 8.24M |
| Receivables | - | 5.98M | 7.14M | 6.58M | 7.20M |
| Total Liabilities | - | 12.42M | 12.73M | 9.81M | 11.04M |
| Current Liabilities | - | 4.18M | 6.37M | 6.57M | 6.08M |
| Long Term Debt | - | 6.65M | 5.00M | 2.92M | 4.50M |
| Total Debt | - | 8.23M | 7.87M | 5.12M | 4.71M |
| Total Equity | - | 52.00M | 31.22M | 60.42M | 66.43M |
| Shares Outstanding | - | 20.88M | 21.37M | 30.04M | 36.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -25.80M | -22.61M | -23.45M | -38.21M |
| Investing Cash Flow | -593.00K | 0 | - | 0 | -242.00K |
| Financing Cash Flow | - | 7.03M | 1.76M | 54.70M | 41.14M |
| Capital Expenditure | -593.00K | - | - | - | -242.00K |
| Free Cash Flow | - | -25.80M | -22.61M | -23.45M | -38.45M |
| Net Change in Cash | - | -18.77M | -20.85M | 31.24M | 2.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 45.2% | 59.9% | 65.9% | 70.8% |
| Operating Margin % | - | -443.1% | -398.0% | -309.6% | -256.3% |
| Net Margin % | - | -429.1% | -393.4% | -260.4% | -264.4% |
| ROE % | - | -55.1% | -90.7% | -46.0% | -64.1% |
| ROCE % | - | -49.1% | -76.2% | -51.9% | -57.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PROF
Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month –TORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” …
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, wil…
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be high…
Profound Medical Corp. (PROF) Dropped Despite High Potential
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outper…
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to i…
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoringTORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Prof…
PROF — Frequently Asked Questions
What is the current share price of PROF?
As of 2026-08-05 17:25 PDT, PROF trades at $7.99 on NASDAQ/NYSE. Its 52-week range is $3.87 to $8.65.
What is the market capitalisation of PROF?
PROF has a market capitalisation of $289.99M on NASDAQ/NYSE.
What is the P/E ratio of PROF?
PROF trades at a trailing price-to-earnings (P/E) ratio of -5.67. Its price-to-book (P/B) ratio is 4.36.
What is the return on equity (ROE) of PROF?
PROF has a return on equity (ROE) of -64.08%. Its return on capital employed (ROCE) is -57.78%.
Is PROF a good stock to buy?
This page provides a data-driven analysis of PROF, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.